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Background: Allogeneic stem cell transplantation (alloSCT)
for multiple myeloma (MM) can offer prolonged remission
and may have curative potential. Overproduction of the dis-
ease speciﬁc clonal serum free light chains by malignant
plasma cells (involved free light chain, iFLC) is a marker of
disease activity. Underproduction of the uninvolved serum free
light chain (uFLC, from non-malignant plasma cells) is a
marker of MM mediated immune suppression. Early predic-
tion of relapse after allogeneic SCT remains a challenge, and is
important for prognostic and therapeutic purposes. We hy-
pothesized that sustained iFLC suppression at 12months post-
alloSCT would be associated with improved survival.
Methods: The primary cohort was 50 consecutive patients
treated with allogeneic SCT from two institutions. This was
selected from a total of 60 patients with patients excluded for
death (n¼6) or relapse (n¼4) prior to one year. Data was
collected retrospectively 2005-2010 and then prospectively
from 2010-2012. Baseline and follow-up serum FLC (at 3
month intervals) were correlated with overall survival (OS).
Patients were considered to have a “suppressed” FLC if the
serum iFLC was reduced below the uninvolved FLC at 12
months post-alloSCT. OS was measured from 12 months
post-alloSCT using Kaplan-Meier plots and the 2 groups werecompared using log-rank test. A step-wise backward cox-
proportional hazards model was used adjusting for age,
CD34+ stem cell dose, conditioning regimen (myeloablative
vs. reduced intensity), graft versus host disease prior to one
year, disease risk by FISH (standard vs. high risk), Interna-
tional Staging System (standard risk vs. high risk) and disease
status prior to SCT (complete remission vs. no complete
remission).
Results: Median follow-up time was 40.0 months from
transplant (12-95.6 months). Longer duration of iFLC sup-
pression was associated with superior outcomes. Patients
without sustained iFLC suppression at one year post-SCT had
worse OS (p¼0.03, Figure 1). The 2-y OS in the sustained iFLC
suppression cohort (95% [95% CI 86-NA]) was signiﬁcantly
superior to the non-sustained iFLC suppression cohort (70%
[95% CI 57-99]) (P¼0.03, Figure 1). By univariate analysis,
there were no baseline characteristic differences. By multi-
variate analysis, lack of iFLC suppression at 1-year post-
alloSCT was associated with signiﬁcantly increased mortality
(HR 7.01, 95% CI 1.21-40.8, p¼0.03). Patients with iFLC re-
covery prior to one year had increased relapse risk compared
to sustained iFLC suppression (HR 10.4, 95% CI 2.95-36.6,
p¼0.0003).
Conclusions: Sustained serum iFLC suppression at one year
relative to the uFLC is a predictive marker of outcomes
following alloSCT for MM. Early recovery of iFLC may be an
indicator of disease progression following alloSCT, thus
identifying patients who may beneﬁt from preemptive in-
terventions to prevent post-transplant relapse.78
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Figure 1. PFS is decreased in patients who receive alemtuzumab
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Background: High-throughput sequencing (HTS) of anti-
body gene rearrangements is an emerging tool for minimal
residual disease (MRD) monitoring in B cell malignancies in
which the malignant clone harbors a monoclonal Ig heavy
chain (IgH) and/or light chain (k or l) rearrangement. This
approach has shown promise in B-ALL and CLL, but appli-
cation of Ig HTS to clinical multiple myeloma (MM) samples
has not been demonstrated previously.
Approach:We conducted HTS of PCR-ampliﬁed IgH (VDJ and
DJ) and k/l (VJ) rearrangements from bone marrow aspirates
(BMA) of patients with MM (n¼9), MGUS (n¼1), and lym-
phoplasmacytic lymphoma (n¼1), and peripheral blood (PB)
of a patient with plasma cell leukemia (n¼1). In 9/12 samples,
an aliquot was enriched for CD138+ cells by immunomagnetic
separation and analyzed separately. Dominant clones from
enriched and un-enriched aliquots were compared to verify
the malignant clonotype sequence. Disease burden in un-
enriched samples was also evaluated by microscopy (BMA/PB
smear) and ranged from 0 (hemodilute) to 37%.
Results: In 11/12 samples, a clearly dominant IgH and/or k/l
rearrangement (>2.7% of total sequences, range 2.7-99.9%)
was identiﬁed with clear separation from background fre-
quency (at least 2.7-fold higher frequency than next most
common clone). One sample exhibited an oligoclonal reper-
toire with no clearly dominant sequence. In 9/9 cases with
paired CD138-enriched samples, the dominant sequences in
the enriched and un-enriched samples were identical, indi-
cating successful identiﬁcation of the malignant clonal Ig
rearrangements in the un-enriched sample. Results were
largely consonant with clinical data, though in one IgG-l
MM sample, no dominant, productive l rearrangement was
detected, and in one IgG-k MM sample, no dominant, pro-
ductive heavy chain rearrangement was detected. This may
be due to mutations at primer-binding sites in these rear-
rangements. In both cases, alternative clone-tracking se-
quences were available from the other loci (i.e., IgH in the
ﬁrst case and k in the second). In 7/12 cases, >1 dominant
sequence among the IgH (VDJ and DJ), k, and l rearrange-
ments was identiﬁed that would be suitable for longitudi-
nally tracking the malignant clone.
Conclusion: HTS of Ig heavy and light chain rearrangements
can successfully identify the MM clone in clinical specimens,
including those with low MM burden. Application of this
technique to MRD evaluation in MM warrants further
development.
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Backgrounds: Despite recent improvements in the therapy
of mantle cell lymphoma, relapsed and refractory disease
still portends a dismal prognosis. Allogeneic stem cell
transplantation (allo-SCT) represents the only potentially
curative therapy in this setting. The aim of this report was to
evaluate the results of reduced-intensity-conditioning (RIC)
allo-SCT in a retrospective cohort of patients from a single
institution.
Patients and Methods: Twenty-nine patients (median age
58 years, range 34-71) undergoing RIC allo-SCT from April
1999 to May 2013 are included in this retrospective analysis.
Themedian number of previous lines of therapywas 5 (range
1-6) with 13 (45%) of patients having previously failed an
autologous SCT. Twenty-six patients (90%) had chemo-
sensitive disease at allo-SCT (CR¼17, PR¼9) and 3 (10%) had
stable disease. The second line International Prognostic In-
dex (sIPI) was 0 in 19 patients (65%) and 1 in 9 patients
(31%). Data was missing in 1. RIC regimens included cyclo-
phosphamide/ ﬂudarabine/ TBI 200cGy with (n¼17) or
without (n¼4) peri-allo-SCT rituximab and melphalan/ ﬂu-
darabine with (n¼6) or without (n¼2) alemtuzumab. All
patients received unmodiﬁed grafts from a matched related
(n¼12), matched unrelated (n¼10) or mismatched unrelated
(n¼7) donor. Progression-free (PFS) and overall (OS) survival
were calculated from the time of allo-SCT. Kaplan-Meier
survival curves and a permutation-based logrank test were
used to compare PFS and OS based on alemtuzumab use and
the sIPI.
Results: All but one patient engrafted with full donor
chimerism. The cumulative incidences (CI) of grade II-IV
acute GVHD at days +100 and +180were 36% (95%CI: 19-53%)
and 46% (95%CI: 27-64%), respectively. The CI of chronic
GVHD at 1 and 2 years was 20% (95%CI: 7-38%) and 29% (95%
CI: 12-49%), respectively. The CI of progression of disease and
non-relapse mortality at 2 years were 32% (95%CI: 15-51%)
and 19% (95%CI: 7-37%), respectively. With a median follow-
